Tag
This study reveals heterogeneous clinical phenotypes in mild-to-moderate COPD, demonstrating significant variability in exacerbation risk and lung function decline, emphasizing precision medicine for early intervention.
This review synthesizes evidence on the feasibility, acceptance, and clinical outcomes of pulmonary telerehabilitation models in COPD, highlighting technical reliability, patient adherence, and clinical benefits from recent trials, includin
Sputum eosinophilia is linked to increased asthma-specific health services use, while neutrophilic inflammation drives hospitalizations in COPD. Understanding these inflammatory patterns aids personalized management and resource planning.
This prospective Chinese cohort study found that airway mucus plugs on chest CT are linked to increased risk of exacerbations and COPD development, even in individuals with preserved spirometry, highlighting their prognostic value in early
SPIROMICS study demonstrates that progression of CT-detected emphysema subtypes over one year independently predicts accelerated FEV₁ decline, offering valuable intermediate endpoints for COPD clinical trials.
This study reveals that COPD poses a greater risk to bone health than T2DM, with combined COPD and T2DM further increasing osteoporosis and fracture risk, especially in men, emphasizing the need for targeted bone health screening.
Metered-dose liquid nitrogen cryospray significantly improves quality of life and reduces severe exacerbations in COPD patients with chronic bronchitis, with a favorable safety profile demonstrated in a recent sham-controlled trial.
Quantitative CT-defined mucus plugs combined with emphysema severity stratify COPD patients into distinct subtypes that predict risk of acute exacerbations, enabling personalized risk assessment and targeted preventive strategies.
This review synthesizes recent evidence on quantitative CT markers of mucus plugging and emphysema in COPD, highlighting their combined impact on acute exacerbation risk and clinical heterogeneity, and discusses implications for personalize
Astegolimab, an anti-ST2 monoclonal antibody, significantly reduced moderate/severe exacerbations in COPD patients with frequent exacerbations in pooled ALIENTO and ARNASA analyses, showing promise for targeting the IL-33/ST2 pathway with g
Dupilumab significantly reduces emergency visits, hospital admissions, and systemic corticosteroid use in COPD patients with type 2 inflammation, offering a promising therapeutic option to mitigate exacerbation-associated morbidity.
This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.
A recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.
A recent study demonstrates that defining COPD exacerbation risk by any moderate or severe event over two years improves prediction accuracy and clinical decision-making compared to the standard one-year criteria.
A large UK cohort study reveals that beta-blockers reduce mortality in COPD patients with heart failure or ischemic heart disease, but concurrent long-acting beta-agonists may attenuate this benefit.
This study uses single-cell RNA sequencing of bronchoalveolar lavage cells to reveal immune dysregulation in COPD, highlighting profibrotic macrophages and monocytes as key players in airway remodeling and gas exchange impairment.
A single moderate COPD exacerbation markedly increases future exacerbation risk and long-term mortality, justifying its reclassification as high risk per GOLD 2026 guidelines and supporting refined risk stratification for better clinical ma
A nationwide cohort study found that SGLT2 inhibitor initiation was associated with a 27% lower risk of incident lung cancer in patients with COPD and type 2 diabetes compared with sulfonylureas.
Mosaic loss of Y chromosome (mLOY) in men is strongly associated with diminished lung function, increased emphysema severity, and faster epigenetic aging, positioning mLOY as a novel biomarker for respiratory aging and COPD risk in males.
A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.
